老年患者における新しい経口抗凝固剤の実際の安全性評価:河南省の副作用モニタリングセンターからの証拠
Dexian Ma1, Chen Chen2, Mingyang Sun3
1Center for Drug Reevaluation of Henan, Zhengzhou, People's Republic of China.
Journal of pharmaceutical policy and practice
|September 5, 2025
まとめ
リバロキサバンやダビガトランエテキサートのような新しい経口抗凝固薬 (NOAC) は,主に出血の副作用を引き起こす可能性があります. 安全な臨床使用には,特に高齢の患者において,強化された医薬品警戒と個別化された投与が不可欠である.
科学分野:
- 薬理学について
- 臨床薬局
- 薬物安全性
背景:
- 新しい経口抗凝固剤 (NOAC) がますます処方されていますが,包括的な副作用のデータは限られています.
- NOACに関連する副作用 (ADRs) を理解し,軽減するために,マーケティング後の監視は不可欠です.
研究 の 目的:
- リバロキサバンとダビガトランエテキサートに関連した副作用を,実際のデータに基づいて分析し,報告する.
- 一般的な臨床的症状を特定し,NOACに関連する副作用の因果関係を評価する.
主な方法:
- 2018年から2023年の間に報告されたNOACに関連するADRの329件の遡及分析.
- 地方食品医薬品局を通じて医療機関から収集されたデータです.
- リバロキサバン (281例) とダビガトランエテキサート (48例) を含めた.
主要な成果:
- 重篤な副作用は21. 6%の症例で発生した.
- 胃腸出血,出血,歯茎出血,凝固障害,エキモシスなど,一般的な副作用でした.
- 原因の評価は,NOACsと重篤な副作用との間には,ほとんどの場合,非常に可能性のある,または可能性のある関係を示した.
結論:
- NOACの使用に特に注意が必要です.
- NOACの安全性を監視するために,医薬品監視システムの強化は不可欠です.
- 臨床的安全性と合理的な薬物使用を高めるために,個別化された薬物療法が推奨されます.
関連する概念動画
Pharmacovigilance
981
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
981
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
869
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
869


